Session with Dr Anil Koul

Speaker Sessions
July 20, 2017 | 6:30 PM - 8:00 PM | Thursday
Mohali: Pushpagiri; Hyderabad: AC2 MLT
Open to Public
Dr. Anil Koul, Director, CSIR-IMTech, is visiting ISB Campus (Mohali) on 20th July 2017 at 06:30 PM. He will be delivering a talk on - Discovery and development of bedaquiline for treatment of drug-resistant tuberculosis-value of innovation. Prior to taking the charge of Director, CSIR-IMTech, Dr Anil Koul was Senior Director & Head, Respiratory Infections Discovery group at global healthcare giant Johnson & Johnson. He has more than 16 years of experience in pharmaceutical drug discovery research and clinical development. He obtained his Ph.D. from Max-Planck Institute for Biochemistry in Munich, Germany and Delhi University. He has been a key scientist in discovery and clinical development of SIRTUROTM (generically called Bedaquiline)- the first tuberculosis drug to be granted approved by United State FDA and EU in last 40 years. Dr. Koul is a visiting professor at Faculty of Sciences at Free University of Amsterdam, Netherlands. He has featured in Voice of America’s scientific radio news analysis on challenges in drug development for neglected diseases.

About IMTech
The Institute of Microbial Technology (IMTech) is based out of Chandigarh, and is a constituent of Council for Scientific and Industrial Research (CSIR). The Institute is involved in cutting-edge research in the areas of biological sciences and microbial biotechnology, with focus on Immunity, Protein-Design and Engineering, and Bioinformatics.

The Session would be highlighting the challenges of Anti-microbial resistance (AMR) faced by the world presently, and the value of Innovations in developing potential new drugs for infectious diseases. It would be great learning experience for all.